Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ROCKVILLE,Md. and SUZHOU,China,Nov. 17,2024-- Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in discovering,developing and commercializing therapies to address global unmet med